An earlier article argued that the gap between a speciality clinic's profit and its enterprise value is a gap in structure, not in clinical quality — and that structure, unlike reputation, can be built deliberately. Document the clinical model. Build demand that belongs to the institution. Put a management function in place before the second site rather than after the first crisis. All of that is right. And almost none of it pays for itself at a single clinic.
Consider what a real management layer contains: a finance function with a proper grip on pricing, cost and capital; revenue cycle and claims; recruitment and retention of nursing and clinical staff; marketing that generates demand rather than announcing that the clinic exists; referral development across general practitioners, corporates and regional channels; clinical systems; procurement; payer contracting. Resourced credibly, that capability costs well into the high hundreds of thousands of dollars a year. Set against a single clinic producing S$2.5 million of revenue, it is indefensible. Shared across seven clinics, its core costs each of them something in the order of S$100,000 a year — roughly the price of one experienced practice manager, for a capability no practice manager can supply — while the functions that generate volume and procurement savings return more than they consume. The management layer is not expensive. It is indivisible.
But shared overhead is the smallest part of the case, and advisers who lead with it undersell the model. The deeper value is clinical: a group of specialists functions as one large practice in a way no referral network of independents ever quite does. Serious illness is rarely a single-specialist event. A colorectal cancer patient will touch gastroenterology, surgery, oncology, imaging and anaesthesia within weeks; a cardiac patient moves between cardiology, cardiothoracic surgery and rehabilitation. In an independent practice, each handover is a referral out — revenue leaving the clinic, and a patient handed across a gap that no one formally owns. Inside a group, the same episode stays within the institution: the patient experiences one coordinated pathway rather than five waiting rooms, the clinical record travels intact, and the professional-fee chain — consult, scope, surgical fee, oncology follow-up — accrues to the group in which every doctor holds a stake, even where the facility economics sit with the hospital. Extending that capture is precisely why mature platforms build their own ambulatory capability: endoscopy suites, day surgery, imaging and the rest.
The same logic applies to where patients come from. Corporate contracts, third-party-administrator arrangements and cross-border referral channels are institutional relationships: negotiated once, demanding service standards and claims infrastructure a solo practice struggles to sustain, and delivering volume to every clinic in the group. Insurer panels remain per-doctor, but the group's claims discipline, pre-authorisation machinery and track record make empanelment faster and the administrative burden bearable, and the group can manage payer mix. In a well-built group, a substantial share of each clinic's patients arrives through channels that no individual clinic could have opened alone. And the group answers the question that haunts every practice: what happens when the doctor is away. Colleagues provide cover without revenue following the founder out of the door; peers review each other's work, which is both a clinical discipline and something acquirers pay for. And the group is the natural landing place for the public-sector consultant going private, with an income floor and built demand instead of a cold start. None of this appears on a fee schedule. All of it compounds.
A platform is not a merger, and it is not a sale. In its usual form there is a holding company, a set of member clinics, and a management company serving all of them. Each clinic remains a distinct operating unit with its own doctor, patients and profit and loss; the management company supplies the shared machinery; the holding company owns the clinics and the doctors hold equity. It is the form the region's consolidators have converged on in one variation or another, and it is the ownership question inside it that founders find difficult.
Joining a platform means owning less of the clinic you built. For a founder who has spent fifteen years building a name, that is not a technical adjustment; it is a genuine loss. The question is not whether the founder gives up ownership. It is what the share he keeps is worth against the whole he gives up.
On that question the market data is consistent. In the US, published M&A data shows practices earning under US$1 million of EBITDA transacting at five to seven times, while platform-scale groups command eleven to thirteen; private equity's entire physician-services playbook is built on that spread. The same gradient is visible in Asia, even if the data is thinner. Run the illustration: a clinic producing S$1 million of maintainable earnings after the doctor is paid a market rate for his clinical work might, as a standalone and founder-dependent practice, change hands at six times — if it changes hands at all. Two-thirds of the same earnings, sitting inside a structured group valued at eleven times, is worth more than the whole clinic standing alone. And the comparison flatters the standalone case: in practice the group's referral engine, panels and procurement raise the clinic's earnings as well as its multiple. The founder who keeps everything ends up with less than the founder who keeps a majority of something institutional.
The re-rating is earned, not granted, and this is where the concept is most often abused. What earns the premium is everything described above — the pathway that keeps the episode inside the group, demand that belongs to the institution, panels and fee schedules negotiated once for everyone, management that is not any of the doctors, several independent earning centres so that no single departure is fatal, and numbers that survive diligence. Strip those out and a platform is a shared logo over unchanged practices. Singapore's consolidators have spent a decade paying real money for majority stakes in single-doctor specialist clinics — HC Surgical's successive acquisitions of endoscopy and surgical practices, HMI's majority stake in Eagle Eye Centre — proof of what acquirers will pay for control of clinic earnings. But acquisition is not integration, and the market has priced that too: a listed vehicle holding a collection of 51% stakes in unchanged single-doctor practices earns no re-rating, however many it buys.
How the doctor's ownership is engineered is a design choice, not a formula, and the market runs on several instruments. Some groups issue every doctor equity in the holding company itself, the full-partnership logic of the professional services firm: maximum alignment across the group, at the cost of dilution with each new joiner and economics that average everyone's performance. Others leave the doctor a substantial stake in his own clinic while the group takes control, which keeps incentives sharp and local but binds the group together more loosely. Others separate control from economics through share classes, so the group consolidates cleanly while the doctor's return tracks the clinic he personally builds. And much can be done contractually — profit shares, earn-outs, consideration paid in group shares with escrows and service conditions. Each instrument trades alignment against precision against simplicity, and the right answer depends on who the doctors are and where the group intends to end up. The design principles, however, do not move: control must consolidate, because a cap table of equal partners with mutual vetoes is not buyable at any multiple; and economics must track contribution, because the doctor who joins first and builds hardest will not stay for an averaged share of everyone else's ramp.
The other half of the trade is capital, and founders consistently underestimate it. Building a speciality clinic properly — fit-out, equipment, systems, licensing — consumes several hundred thousand dollars before the first patient, then loses money through a ramp that realistically runs three to five years. In most platform structures that build is funded at group level, management fees are waived while the clinic is loss-making, and the doctor's income is floored through the early years. His own cheque is a fraction of the cost: he takes structure risk rather than capital risk, which for a clinician in his forties is a materially different proposition. What he surrenders is not money but sole authority — pricing, brand, senior hiring and capital allocation become decisions taken with him rather than by him. Some founders find that intolerable.
It is also worth being clear about what kills these structures, because plenty fail. Retention is the first and largest: a platform's entire claim is that its value does not depend on any one doctor, yet its assets are doctors, and equity terms that let a clinician crystallise and leave simply recreate key-person risk at scale. Valuation is the second — every new clinic admitted requires the group to be valued, and that is an argument with existing holders each time. Dilution is the third, felt most sharply by those who took the earliest risk. All of it is a design constraint to be cleared before the structure is built, not after.
So the choice facing a successful specialist is not really whether to give up ownership. It is whether to own all of something priced as a job, or most of something priced as an institution. For the founder who intends to practise until he stops and never sell, the first is entirely rational, and always has been. For everyone else the arithmetic is consistent and unsentimental: one hundred per cent of a founder-dependent clinic is the most expensive thing a specialist can own.
KPA works with speciality clinic founders and healthcare investors across Southeast Asia on the structures this article describes — from clinic unit economics and group financial modelling through ownership design and capital structure to exit. Our work is concerned with where value actually sits in a clinical business, how ownership should be arranged so that it survives the people who created it, and what a founder should reasonably expect to keep. The distance between a profitable practice and a valuable one is a question of structure, and that is where our work is grounded.